Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

PHASE4CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

September 21, 2023

Study Completion Date

September 21, 2023

Conditions
Multiple Sclerosis
Interventions
DRUG

Mavenclad®

No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568\_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).

Trial Locations (46)

Unknown

Liverpool Hospital, Liverpool

John Hunter Hospital, New Lambton

Klinikum Klagenfurt, Klagenfurt

Paracelsus Medical University Salzburg, Salzburg

University of Alberta, Edmonton

Children's Hospital, London Health Sciences Centre- Pediatrics, London

Montreal Neurological Hospital, Montreal

MS Clinical Trials Group, Vancouver

Fakultni nemocnice Brno, Brno

Fakultni nemocnice u sv. Anny v Brne, Brno

FN Hradec Kralove, Hradec Králové

Nemocnice Pardubickeho kraje, a.s. Pardubicka nemocnice, Pardubice

Fakultni nemocnice v Motole, Prague

Tampere University Hospital, Tampere

Turku University Hospital, Turku

CHU de Montpellier Hôpital Gui de Chauliac- Département de Neurologie, Montpellier

CHU Nice - Hôpital Pasteur, Nice

CHU Nîmes, Nîmes

CHU de Poissy, Poissy

CHU de Pontchaillou, Rennes

Hôpital Civil, Strasbourg

Universitätsklinikum Carl Gustav Carus, Dresden

Universitätsklinikum Essen, Essen

Neurologische Praxis Eppendorf, Hamburg

Medizinische Hochschule Hannover, Hanover

Klinik und Poliklinik fur Neurologie, Leipzig

Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo, Szeged

Barzilai Medical Center, Ashkelon

Rambam MC, Haifa

Sheba Medical Centre, Tel Litwinsky

"Università G. D'Annunzio Chieti-Pescara Ospedale Cliniciz", Chieti

"Dipartimento di internistica clinica e sperimentale Flaviano MagrassiUniversità degli studi della Campania Luigi Vanvitelli", Napoli

IRCSS Neuromed Istituto Neurologico Mediterraneo, Pozzilli

Samodzielny Publiczny Szpital Kliniczny nr 7 SUM, Katowice

Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin

Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanislawa Szyszko SUM w Katowicach, Zabrze

Hospital de Cruces, Barakaldo

Hospital Vithas NISA Sevilla, Castilleja de la Cuesta

Hospital Clinico San Carlos, Madrid

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

Hospital La Fe, Valencia

Sahlgrenska Universitetssjukhus, Gothenburg

Akademiskt Specialist Centrum - Centrum för Neurologi,, Stockholm

Queen Elizabeth Hospital, Birmingham

University Hospital of Wales, Cardiff

Sheffield Teaching Hospitals Sheffield, Sheffield

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04783935 - Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension) | Biotech Hunter | Biotech Hunter